Fotagliptin

Fotagliptin
Clinical data
Other names	SAL067
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[[3-[(3R)-3-Aminopiperidin-1-yl]-6-methyl-5-oxo-1,2,4-triazin-4-yl]methyl]-4-fluorobenzonitrile;
CAS Number	1312954-58-7 ;
PubChem CID	53258570 ;
Chemical and physical data
Formula	C17H19FN6O
Molar mass	342.378 g·mol−1

Last updated July 16, 2025

Fotagliptin (SAL067) is a DPP-4 inhibitor under development for the treatment of type 2 diabetes. Like other DPP-4 inhibitors, it works by increasing endogenously produced GLP-1 and GIP.^[1]^[2]^[3] In a phase 3 trial it showed similar results as alogliptin.^[4]

References

↑ Wu, Min; Li, Qian-Qian; Zhang, Hong; Zhu, Xiao-Xue; Li, Xiao-Jiao; Li, Ying; Sun, Hai-Gang; Ding, Yan-Hua (June 2021). "Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus" . Clinical Pharmacology in Drug Development. 10 (6): 660–668. doi:10.1002/cpdd.895. ISSN 2160-763X. PMID 33440080. S2CID 231606176.
↑ Fang, Lan; Gao, Zhenguo; Wu, Songgu; Jia, Shengzhe; Wang, Jingkang; Rohani, Sohrab; Gong, Junbo (1 August 2021). "Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization". Ultrasonics Sonochemistry. 76 105634. Bibcode:2021UltS...7605634F. doi:10.1016/j.ultsonch.2021.105634. ISSN 1350-4177. PMC 8261672 . PMID 34218067.
↑ Ding, Yanhua; Zhang, Hong; Li, Cuiyun; Zheng, WenBo; Wang, Meng; Li, Ying; Sun, HaiGang; Wu, Min (3 June 2021). "Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology. 17 (6): 725–731. doi:10.1080/17425255.2021.1915283. PMID 33899649. S2CID 233400233.
↑ Xu, Mingtong; Sun, Kan; Xu, Wenjie; Wang, Chuan; Yan, Dewen; Li, Shu; Cong, Li; Pi, Yinzhen; Song, Weihong; Sun, Qingyuan; Xiao, Rijun; Peng, Weixia; Wang, Jianping; Peng, Hui; Zhang, Yawei; Duan, Peng; Zhang, Meiying; Liu, Jianying; Huang, Qingmei; Li, Xuefeng; Bao, Yan; Zeng, Tianshu; Wang, Kun; Qin, Li; Wu, Chaoming; Deng, Chunying; Huang, Chenghu; Yan, Shuang; Zhang, Wei; Li, Meizi; Sun, Li; Wang, Yanjun; Li, HongMei; Wang, Guang; Pang, Shuguang; Zheng, Xianling; Wang, Haifang; Wang, Fujun; Su, Xiuhai; Ma, Yujin; Zhang, Wei; Li, Ziling; Xie, Zuoling; Xu, Ning; Ni, Lin; Zhang, Li; Deng, Xiangqun; Pan, Tianrong; Dong, Qijuan; Wu, Xiaohong; Shen, Xingping; Zhang, Xin; Zou, Qijing; Jiang, Chengxia; Xi, Jue; Ma, Jianhua; Sun, Jingchao; Yan, Li (2023). "Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial". BMC Medicine. 21 (1): 388. doi: 10.1186/s12916-023-03089-x . ISSN 1741-7015. PMC 10563289 . PMID 37814306.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Wu, Min; Li, Qian-Qian; Zhang, Hong; Zhu, Xiao-Xue; Li, Xiao-Jiao; Li, Ying; Sun, Hai-Gang; Ding, Yan-Hua (June 2021). "Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus" . Clinical Pharmacology in Drug Development. 10 (6): 660–668. doi:10.1002/cpdd.895. ISSN 2160-763X. PMID 33440080. S2CID 231606176.

[2] Fang, Lan; Gao, Zhenguo; Wu, Songgu; Jia, Shengzhe; Wang, Jingkang; Rohani, Sohrab; Gong, Junbo (1 August 2021). "Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization". Ultrasonics Sonochemistry. 76 105634. Bibcode:2021UltS...7605634F. doi:10.1016/j.ultsonch.2021.105634. ISSN 1350-4177. PMC 8261672 . PMID 34218067.

[3] Ding, Yanhua; Zhang, Hong; Li, Cuiyun; Zheng, WenBo; Wang, Meng; Li, Ying; Sun, HaiGang; Wu, Min (3 June 2021). "Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology. 17 (6): 725–731. doi:10.1080/17425255.2021.1915283. PMID 33899649. S2CID 233400233.

[4] Xu, Mingtong; Sun, Kan; Xu, Wenjie; Wang, Chuan; Yan, Dewen; Li, Shu; Cong, Li; Pi, Yinzhen; Song, Weihong; Sun, Qingyuan; Xiao, Rijun; Peng, Weixia; Wang, Jianping; Peng, Hui; Zhang, Yawei; Duan, Peng; Zhang, Meiying; Liu, Jianying; Huang, Qingmei; Li, Xuefeng; Bao, Yan; Zeng, Tianshu; Wang, Kun; Qin, Li; Wu, Chaoming; Deng, Chunying; Huang, Chenghu; Yan, Shuang; Zhang, Wei; Li, Meizi; Sun, Li; Wang, Yanjun; Li, HongMei; Wang, Guang; Pang, Shuguang; Zheng, Xianling; Wang, Haifang; Wang, Fujun; Su, Xiuhai; Ma, Yujin; Zhang, Wei; Li, Ziling; Xie, Zuoling; Xu, Ning; Ni, Lin; Zhang, Li; Deng, Xiangqun; Pan, Tianrong; Dong, Qijuan; Wu, Xiaohong; Shen, Xingping; Zhang, Xin; Zou, Qijing; Jiang, Chengxia; Xi, Jue; Ma, Jianhua; Sun, Jingchao; Yan, Li (2023). "Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial". BMC Medicine. 21 (1): 388. doi: 10.1186/s12916-023-03089-x . ISSN 1741-7015. PMC 10563289 . PMID 37814306.

[1]

[2]

[3]

[4]